|

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

RECRUITINGSponsored by Neurology Center of New England P.C.
Actively Recruiting
SponsorNeurology Center of New England P.C.
Started2024-08-13
Est. completion2027-09-30
Eligibility
Age55 Years – 80 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06681623

Summary

The purpose of this study is to evaluate the safety of ublituximab use in the older MS adult population, as measured by incidence of infection rate

Eligibility

Age: 55 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Signed informed consent
* Aged 55-80 years old
* Diagnosis of RMS according to the 2017 Revised McDonald criteria
* Anticipated to begin treatment with or newly treated with ublituximab (within 6 months prior to study entry) according to the local label

Exclusion Criteria:

* Active participation in an interventional clinical trial for MS
* Received initial dose of ublituximab more than 6 months prior to study entry
* History of life-threatening infusion reaction on any anti-CD20 therapy
* Evidence of clinically significant chronic or ongoing active viral, bacterial, or fungal infectious disease requiring long term systemic treatment, or any history of recurrent infection within 6-12 months prior to initiation of ublituximab

Conditions2

Multiple SclerosisMultiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Locations1 site

Neurology Center of New England P.C.
Foxborough, Massachusetts, 02035
Rachel ODonnell781-551-5812ResearchNCNE@myneurodr.com

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.